Skip to content
Review Open access

Treatment goals for pharmacoresistant epilepsy in childhood and youth - The parental perspective.

Sep 2026 · Epilepsy & Behavior · Vol 185, pp. 111259 · 0 citations · 34 references
Medicine

TL;DR

While seizures remain a central concern, families prioritize developmental, behavioral, sleep-related, and psychosocial domains nearly as strongly as current care models and literature emphasize HRQoL measurement but rarely capture explicit parental goals.

Abstract

Purpose

Research on pharmacoresistant epilepsy including developmental and epileptic encephalopathies (DEE) predominantly focuses on seizure control and health-related quality of life (HRQoL), while explicit parental goals concerning treatment outcomes as well as perceived resources and support needs remain somewhat underrepresented. We aimed to systematically assess parental priorities, perceived resources, and support needs in families of children with therapy-resistant epilepsies.

Methods

We conducted an online survey (September-October 2025). Parents ranked 14 symptom domains according to personal relevance, rated opportunities to address these topics in different healthcare settings and evaluated support needs across medical and psychosocial domains. Descriptive and non-parametric statistical analyses were performed, including subgroup comparisons by age and Dravet/SCN1A status.

Results

A total of 224 questionnaires were analyzed (mean child age 12.0 ± 6.3 years; 34 different genetic etiologies, including 40 Dravet/SCN1A patients). Seizures were the top concern when it came to what most affects families' daily lives. However, cognitive development, sleep, and externalizing behavioral problems consistently followed, indicating a multidimensional goal structure beyond seizure control. Subgroup analyses revealed largely similar priorities. Parents reported sufficient time to address medical issues in specialized settings but expressed substantial unmet needs in psychological support for the child, themselves, and the family. Free-text responses highlighted deficits in access to therapies, educational inclusion, care coordination and psychosocial support.

Conclusions

While seizures remain a central concern, families prioritize developmental, behavioral, sleep-related, and psychosocial domains nearly as strongly. Current care models and literature emphasize HRQoL measurement but rarely capture explicit parental goals. Systematic goal elicitation and genuine interdisciplinary, family-centered care are needed to alleviate the burden on families through appropriate treatment planning.

Read PDF

Similar papers

Open access Sep 2026

Living with developmental and/or epileptic encephalopathies: exploring health-related quality of life in children, youth, and their families

Attention to non-seizure outcomes in Developmental and/or Epileptic Encephalopathies (DEs, EEs, DEEs) is growing, and there is increasing interest in understanding key determinants of health-related quality of life (HRQoL) in this population. This study investigates personal and family HRQoL in a real-world pedia...

L. Bergonzini, F. Sperandeo, S. Lelli et al. · 0 citations
Open access Aug 2026

A study on the quality of life of children with epilepsy and the impact of disease on family functioning

Background: Epilepsy is one of the most common chronic neurological disorders in childhood and is associated with significant physical, emotional, social, and educational consequences. Beyond seizure control, children with epilepsy often experience impaired health-related quality of life (HRQoL), while their caregivers...

Aveepsa Prusty, S. Agrawal, Suryakanta Swain · 0 citations
Open access Oct 2026

What shapes health-related quality of life in drug-resistant epilepsy? Clinical, emotional, and cognitive predictors.

PURPOSE Clinical and psychological factors associated with health-related quality of life (HRQoL) in drug-resistant epilepsy (DRE) are well established; however, the contribution of alexithymia and specific neurocognitive domains remains less well characterized. This study aimed to examine clinical, emotional, and neur...

Katerina Poprelka, Panagiota-Eleni Tsalouchidou, Konstantina Stavrogianni et al. · 0 citations
Review Aug 2026

Efficacy of synthetic ACTH in confirmed and presumed monogenic developmental and epileptic encephalopathies.

It is suggested that ACTH may be associated with sustained electroclinical improvement in selected genetically defined DEEs, and the identified network-level interactions between ion channel-related genes and intracellular signaling pathways provide a potential molecular framework for understanding variability in treat...

Çisem Duman Kayar, Sinan Akbaş, Fulya Kürekçi et al. · 0 citations
Review Sep 2026

Treatment gap in epilepsy is predicted more by patient perceptions than disease burden: Population-based study from rural India.

Perception-related variables, namely unawareness regarding ASM side-effects, healthcare disengagement, faith-healing beliefs, and preference for non-specialist care, were found to be independent predictors of primary TGap.

Chaturbhuj Rathore, Harsh Patel, Neeraj Baheti et al. · 0 citations
Sep 2026

Assessing Impact of Health System Specialty Pharmacy Support on Initiation of Vigabatrin Therapy for Infantile Epileptic Spasms Syndrome.

PURPOSE Infantile epileptic spasms syndrome (IESS) is a severe form of pediatric epilepsy requiring urgent diagnosis and treatment. Vigabatrin is a standard therapy but often requires inpatient initiation because of delays in outpatient access due to prior authorization (PA) requirements and distribution restrictions....

Jillian Gould, Kayla Petkus, J. Mytinger et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.